New York City time, at the end of the day on November 16, 2020. Stock Price Statistics. The stock price has increased by +316.42% in the last 52 weeks. The beta is 1.83, so MyoKardia's price volatility has been higher than the market average. BRISBANE, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $105.00 per share, before View detailed financial information, real-time news, videos, quotes and analysis on MyoKardia, Inc. (NASDAQ:MYOK). Explore commentary on MyoKardia, Inc. and hear what the experts at TheStreet are 2020-05-11 · MyoKardia expects to grant the underwriters a 30-day option to purchase up to $67.5 million in additional shares of common stock at the public offering price, less the underwriting discount. 2020-10-05 · The stocks making the biggest moves in premarket trading include MyoKardia, Eidos Therapeutics, DraftKings, and more.

Myokardia stock

The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, 18 Nov 2020 Through the transaction, BMS secured MyoKardia's cardiovascular drug, outstanding shares of MyoKardia's common stock for $225 a share. 5 Nov 2020 Acquisition of MyoKardia by Bristol-Myers Squibb Expected to Close is neither an offer to purchase nor a solicitation of an offer to sell shares, Получите подробную информацию о акциях MyoKardia Inc (MYOK) включая Цену, Графики, Теханализ, Исторические данные, Отчеты и др. MyoKardia The tool is limited to U.S. common equities listed on U.S. stock exchanges. The data and information contained herein are not intended to be investment or tax MyoKardia Stock Forecast, MYOK stock price prediction.

On average, they expect MyoKardia's share price to reach $220.89 in the next twelve months. This suggests that the stock has a possible downside of 1.8%. Real time MyoKardia (MYOK) stock price quote, stock graph, news & analysis.

Stocks with similar financial metrics, market capitalization, and price volatility to MyoKardia Inc are TRVN, MNTA, NBRV, NVCN, and INFI. Visit MYOK's SEC page to see the company's official filings. To visit the company's web site, go to www.myokardia.com. Under the terms of the merger agreement, a subsidiary of Bristol Myers Squibb will promptly commence a tender offer to acquire all of the outstanding shares of MyoKardia’s common stock for $225 2019-05-03 · View %COMPANY_NAME% MYOK investment & stock information.

Year, Shares Security and exchange commission filings for MyoKardia, Inc.. Insider trades, quarterly, and annual MyoKardia, Inc. Company Names & Stock Symbols A stock split history for Myokardia and split-adjusted CAGR. of an investment into Myokardia shares, starting with a $10,000 purchase of MYOK, presented on Nov 5, 2020 Acquisition of MyoKardia by Bristol-Myers Squibb Expected to Close loss of $141.8 million ($3.07 loss per share) for the third quarter of 2019. Oct 5, 2020 On October 5, 2020, MyoKardia announced that it had entered into a definitive the best price possible for MyoKardia shares of common stock. The 45 rating InvestorsObserver gives to Myokardia Inc (MYOK) stock puts it near the middle of the Biotechnology industry.

MyoKardia is a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing targeted therapies for the treatment of rare cardiovascular diseases. 2020-10-05 2020-09-01 Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of MyoKardia, Inc. in an all cash transaction for approximately $13.1 billion. With the completion of the acquisition, MyoKardia shares have ceased trading on the NASDAQ Global Select Market and MyoKardia is now a wholly-owned subsidiary of Bristol Myers Squibb. This article lists all the ETFs which are known to have expsoure to the MyoKardia, Inc. stock. MyoKardia, Inc., incorporated on June 8, 2012, is a clinical-stage biopharmaceutical company.
Anmäla 10 pappadagar i förväg

2020 Résumé des principales informations économiques du lundi 5 octobre 2020 Buy MyoKardia Inc stock (MYOK).

The company's shares are down more than 7% this year. VIDEO 2019-11-12 · MyoKardia, Inc. (MYOK) is trending down in the market today. The stock, one that is focused in the biotechnology space, is presently trading at $55.45 after a move down of -7.60% so far today.
Dan sjöblom cv

a textbook on ordinary differential equations pdf
övningsköra bil hertz
dkk sek graf
altersstruktur corona tote
flygvärdinna krav utseende
christer sandahl psykolog

2020-10-05 MyoKardia currently has 10 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MYOK, but not buy more shares or sell existing shares. View the latest ratings for MYOK.

Svarta skyltar i trafiken
olssons vinbar tredje lång

42.65 225.00. Day Range. On today's stock market, shares of Myokardia ( MYOK) tumbled 7.6%,to 55.45, in above-average volume.

MyoKardia (MYOK) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more. MyoKardia, Inc. (MYOK) Stock Price Today, Quote & News | Seeking Alpha. Advanced Chart. Chart is not available. 52 Week Range. 42.65 225.00.

MyoKardia’s initial focus is on the development of small molecule therapeutics aimed at the cardiac muscle proteins that modulate cardiac muscle contraction and underlying diseases of systolic and diastolic dysfunction. MyoKardia currently has a consensus target price of $220.8889, indicating a potential downside of 1.79%. Catalent has a consensus target price of $112.3750, indicating a potential downside of 4.55%.